Evaluation of diagnostic test for the superficial bladder cancer based intravesical instillation of pirarubicin (THP) prior to transurethral resection (TUR)
Not Applicable
Recruiting
- Conditions
- Superficial bladder cancer
- Registration Number
- JPRN-UMIN000018932
- Lead Sponsor
- Dokkyo Medical University, Department of Urology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
progressive cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method We study to confirm a tendency whether superficial bladder cancer has take THP, and present whether this finding useful for determining a cancerous lesion. For preparation, we inject THP15mg and distilled water 15ml to urinary bladder 30 minitues before for operation. We also perform comperative examination among THP taken lesions, lesions by white light and lesions by NBI histopathologically.
- Secondary Outcome Measures
Name Time Method To evaluate the recurrence rate between THP taken lesions and its untaken lesions at 6, 12 months later from last THP injection date for adjuvant therapy